Nifedipine and Statin Combination: Risk of Muscle Aches

Mechanism of Interaction

Nifedipine may compete with statins for membrane transporters such as P-glycoprotein (P-gp), further increasing statin bioavailability and risk of myopathy, as reported by the American Heart Association 1

Statins alone can cause muscle symptoms in approximately 5-10% of patients, according to the American College of Cardiology 2

Advanced age (especially >80 years), with women at higher risk than men, is a risk factor for statin-nifedipine muscle symptoms, as noted by the American Heart Association 3
Small body frame and frailty are risk factors for statin-nifedipine muscle symptoms, as reported by the American Heart Association 3
Multisystem disease (e.g., chronic renal insufficiency, especially due to diabetes) is a risk factor for statin-nifedipine muscle symptoms, according to the American Heart Association 3
Multiple medications (polypharmacy) is a risk factor for statin-nifedipine muscle symptoms, as noted by the American Heart Association 3
Perioperative periods are a risk factor for statin-nifedipine muscle symptoms, as reported by the American Heart Association 3

If muscle symptoms develop while on statin-nifedipine combination, the American College of Cardiology recommends discontinuing the statin temporarily until symptoms can be evaluated 4
Evaluating for other conditions that might increase muscle symptom risk (e.g., hypothyroidism, reduced renal/hepatic function, rheumatologic disorders, vitamin D deficiency) is recommended by the American College of Cardiology 4
Measuring creatine kinase (CK) levels to assess for muscle damage is recommended by the American College of Cardiology 2
Restarting with a lower dose of the same statin or switching to a different statin with less potential for interaction is recommended by the American College of Cardiology 4
Using a statin less dependent on CYP3A4 metabolism (e.g., rosuvastatin, pravastatin, fluvastatin) is recommended by the American Heart Association 1

Higher risk combinations, such as atorvastatin, lovastatin, and simvastatin with nifedipine, are due to CYP3A4 metabolism, as reported by the American Heart Association 1
Lower risk combinations, such as rosuvastatin, fluvastatin, pravastatin, and pitavastatin with nifedipine, are less dependent on CYP3A4, according to the American Heart Association 1

Instructing patients to report muscle discomfort, weakness, or brown urine immediately is recommended by the American Heart Association 5
Monitoring for muscle symptoms at 6-12 weeks after starting therapy and at each follow-up visit is recommended by the American Heart Association 3
Obtaining CK measurements when patients report muscle soreness, tenderness, or pain is recommended by the American Heart Association 3
Considering the timing of symptoms in relation to exercise, as statin-related myopathy typically persists beyond normal post-exercise recovery period, is recommended by the American College of Cardiology 2